Advanced alveolar soft part sarcoma responds to apatinib
PDF | HTML | How to cite
Metrics: PDF 7290 views | HTML 2160 views | ?
Yong Zhou1,*, Fan Tang1,2,*, Yiying Wang3, Li Min1,2, Yi Luo1, Wenli Zhang1, Rui Shi1, Hong Duan1 and Chongqi Tu1
1 Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China
2 Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA, USA
3 Department of Pathology, West China Hospital, Sichuan University, Chengdu, China
* These authors have contributed equally to this study
Chongqi Tu, email:
Keywords: alveolar soft part sarcoma, vascular endothelial growth factor receptor-2, anti-angiogenesis, chemotherapy resistance, apatinib
Received: January 28, 2017 Accepted: June 08, 2017 Published: June 22, 2017
Alveolar soft part sarcoma (ASPS) is a rare, hypervascular soft tissue sarcoma with a low chemotherapy response rate. Here, we report an ASPS case with multiple lung metastases on initial presentation. The primary tumor, a hypervascular soft tissue mass 4.1×3.2×2.0 cm, located in the right thigh, was resected prior to chemotherapy. The patient suffered disease progression after two cycles of gemcitabine-docetaxel treatment. Immunohistochemical examination of the tumor tissue revealed strong positive staining for vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2). The patient was subsequently treated with apatinib (500 mg/day), a specific VEGFR-2 inhibitor. Treatment was well tolerated, and the patient exhibited a partial response, with the lung metastases reduced in size and number after one month of therapy. To date, 12-month progression-free survival has been achieved. Apatinib may provide an additional treatment option for metastatic ASPS, particularly in cases resistant to other chemotherapeutic options. Furtherstudies with more cases with longer follow-up times will be necessary to determine the clinical efficacy of apatinib for treatment of ASPS.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.